Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

British Journal of Cancer

Volumn 91, Issue 3, 2004, Pages 489-497

  Comella, P ^a   Frasci, G ^a   Carnicelli, P ^b   Massidda, B ^c   Buzzi, F ^d   Filippelli, G ^d   Maiorino, L ^e   Guida, M ^f   Panza, N ^g   Mancarella, S ^d   Cioffi, R ^h  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Ospedale G da Procida   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d Universit degli Studi di Padova   (Italy)

^e San Gennaro Hospital   (Italy)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

^h City Hospital   (Italy)

Author keywords

Doublet regimens; Elderly NSCLC patients; Gemcitabine; Paclitaxel; Vinorelbine

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GEMCITABINE; NAVELBINE; PACLITAXEL;

AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; SURVIVAL; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HEALTH STATUS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 4143145523     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602011     Document Type: Article

References (38)

1. Aapro MS, Extermann M, Repetto L (2000) Evaluation of the elderly with cancer. Ann Oncol 11(Suppl 3): 223-229
2. Alberola A, Cortesi E, Juan O (2002) Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer. Crit Rev Oncol Hematol 44: S31-S41
3. Altavilla G, Adamo V, Buemi B, Marabello G, Maisabo R, Lupo G, Bene A, Bellocco G (2000) Gemcitabine as a single agent in the treatment of elderly patients with advanced non-small cell lung cancer. Anticancer Res 20: 3675-3678
4. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Mlroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Charmichael J (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer. A randomised trial with quality of life as the primary outcome. Br J Cancer 83: 447-453
5. Billingham LJ, Cullen MH (2001) The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol 12: 1671-1675
6. Bunn Jr PA, Lilenbaum R (2003) Chemotherapy for elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 95: 341-343
7. Cox DR (1972) Regression models and life tables. J Royal Stat Assoc 34: 187-220
8. Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Oxer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J, Spiridonitis CK (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 14: 2774-2784
9. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd MR, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17: 3188-3194
10. Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5: 37-42
11. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC (2001) Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 20: 1064-1070
12. Elderly Lung cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66-72
13. Frasci G (2002) Chemotherapy of lung cancer in the elderly. Crit Rev Oncol Hematol 41: 349-361
14. Frasci G, Comella P, Panza N, De Cataldis G, Del Gaizo F, Pozzo C, Gravina A, Ruffolo P, Cioffi R, Marcatili P, Della Vittoria M, Monfardini S, Comella G (1998) Carboplatin-oral etoposide personalised dosing in elderly non-small cell lung cancer patients. Eur J Cancer 34: 1710-1714
15. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis A, Iannelli A (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18: 2529-2536
16. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novelle S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V (2003) Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95: 362-372
17. Hennessy BT, Hanrahan EO, Breathnach OS (2003) Chemotherapy options for elderly patients in advanced non-small cell lung cancer. Oncologist 8: 270-277
18. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA (2003) The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV non-small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98: 779-788
19. Hirsh V, Whittom R, Ofiara L, Desjardins P, Ayoub J, Charpentier D, Small D, Pintos J, Langleben A (2003) Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 97: 2242-2247
20. Isla D, Rosell R, Sanchez JJ, Carrato A, Felip E, Camps C, Artal A, Gonzalez-Larriba JL, Azagra P, Alberola V, Martin C, Massuti B (2001) Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced of metastatic non-small cell lung cancer. J Clin Oncol 19: 1071-1077
21. Kaplan ES, Meier P (1958) Non parametric estimation for incomplete observations. J Am Stat Assoc 53: 557-580
22. Kelly K, Giarritta S, Haynes S, Akerley W, Hesketh P, Wozniak A, Albain K, Crowley J, Gandara DR (2001) Should older patients (pts) receive combination chemotherapy in advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Group trials 9509 and 9308. Proc Am Soc Clin Oncol 20: 329a (abstract #1313)
23. Langer CJ, Vangel J, Schiller DP, Harrington DP, Sandler A, Belani CP, Johnson D (2003) Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (<70 yrs). Proc Am Soc Clin Oncol 22: 639 (abstract #2571)
24. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-366
25. Lichtman SM, Skirvin JA, Vemulapalli S (1999) Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 46: 101-114
26. Lorusso V, Carpagnano F, Frasci G, Panza N, Di Rienzo G, Cisternino ML, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S, De Lena M (2000) Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non small-cell lung cancer. J Clin Oncol 18: 405-411
27. Mantel N (1996) Evaluation of survival data and two new rank of order statistics arising in its considerations. Cancer Chemother Rep 50: 163-170
28. Martin C, Ardizzoni A, Rosso R (1997) Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging Clin Exp Res 9: 297-303
29. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
30. Non Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trial. BMJ 311: 899-909
31. Quoix E, Breton JL, Ducolone A, Depierre A, Lemarie E, Moro D, Neidhardt A-C, Aubert E, Heurtebize N, Germa C (2003) First-line 4-week (4W) versus 3-week (3W) single-agent gemcitabine (GEM) in elderly patients (pts) with NSCLC: a randomized multicenter phase II study. Proc Am Soc Clin Oncol 22: 629 (abstract #2530)
32. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92: 1074-1080
33. Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Algeri R, Bonifazi V, Fioretto ML, Orlandini C, Conte PF (2000) Gemcitabine monotherapy in elderly patients with non-small cell lung cancer. Lung Cancer 27: 75-80
34. Rocha Lima CM, Herndon JE, Clamon G, Green MR (2002) Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 94: 181-187
35. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98
36. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J (1997) Gemcitabine in the treatment of elderly patients with advanced non-small cell lung carcinoma. Sem Oncol 24(Suppl 7): S50-S55
37. Soria JC, Brisgand D, Le Chevalier T (2001) Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination chemotherapy? Ann Oncol 12: 1667-1670
38. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH (2001) Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 92: 2639-2647